GlassScriptPhysician profile
Shane Reynal
NPI 1831651181
$6,500.11
in general payments reported to CMS, 2019-2025
27 companies · $2,550 in 2025
The $2,550 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $316 · 2022: $372 · 2023: $944 · 2024: $2,318 · 2025: $2,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,704 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,704.34 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.27 | 2021-2025 | |
| Amgen INC. | $627.80 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $568.89 | 2022-2025 | |
| Janssen Biotech, INC. | $488.51 | 2023-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $434.07 | 2021-2024 | Sotyktu |
| Leo Pharma INC. | $350.26 | 2024-2025 | Adbry, Anzupgo |
| Incyte Corporation | $335.29 | 2023-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $328.42 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $311.74 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $269.01 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $244.17 | 2023-2025 | |
| Genzyme Corporation | $237.88 | 2023-2025 | |
| Ucb, INC. | $213.03 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $168.99 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.93 | 2023-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $129.49 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Merz North America, INC. | $71.63 | 2024 | |
| Sun Pharmaceutical Industries INC. | $49.22 | 2024-2025 | |
| Galderma Laboratories, L.P. | $37.35 | 2023-2025 | Nemluvio, Oracea, Twyneo |
| Kyowa Kirin, INC. | $33.45 | 2024 | Poteligeo |
| Helsinn Therapeutics (U.S.), INC. | $29.25 | 2022 | |
| Revance Therapeutics, INC. | $27.23 | 2024 | Daxxify |
| Krystal Biotech INC | $26.06 | 2024 | Vyjuvek |
| Integra Lifesciences Corporation | $24.42 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Fresenius Kabi USA, LLC | $22.45 | 2023 | Idacio |
| Botanix Sb INC | $21.64 | 2025 | Sofdra |
| Fidia Pharma USA INC. | $16.66 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Reynal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.